NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool

Description: "NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool", which provides in-depth insights into the Non-Small Cell Lung Cancer (NSCLC) indication. The report provides an estimation of the market size for 2012 along with market forecasts until 2019 for the Asia-Pacific (APAC) region, covering Australia, China, India and Japan.

It also covers disease epidemiology, treatment algorithms, treatment patterns, clinical trial analysis (including failure rates), pipeline analysis, and analysis of deals relevant to NSCLC. The NSCLC market in the APAC region is estimated to have been worth $1.8 billion in 2012 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.3% to reach $2.9 billion by 2019.

The key drivers for this growth include an aging population, an increasing number of NSCLC incident cases and the expected launch of promising therapies. The launch of premium-priced novel antibodies and immunotherapies in the first and second lines of therapy, including Boehringer Ingelheim's Gilotrif, Eli Lilly's necitumumab, Bristol-Myers Squibb's Yervoy (ipilimumab) and nivolumab, Pfizer’s dacomitinib and Novartis’s LDK378 are set to drive the market during the forecast period.

However, the recent implementation of a price ceiling on essential drugs, dominance of generic drugs in India and expected pricing restrictions in China could curtail the NSCLC market in APAC countries.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in Australia, China, India and Japan. It includes:

- A brief introduction to NSCLC, including the disease's pathogenesis, etiology, diagnosis and treatment algorithms
- In-depth analysis of currently marketed drugs for NSCLC, including analysis of their safety, efficacy, treatment patterns and strengths and weaknesses, as well as a heat map comparing them in terms of safety and efficacy
- A comprehensive review of the pipeline for NSCLC, including individual analysis of a number of late-stage pipeline drugs likely to enter the market during the forecast period, analyzed on the basis of phase distribution, molecule type, program type, mechanisms of action and molecular target
- Additional in-depth analysis of pipeline drug clinical trials, by Phase, trial size, trial duration and program failure rate, for each molecule type
- Multi-scenario forecast data of the market to 2019, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets
- Discussion of the drivers of and barriers to market growth
- In-depth analysis of all licensing and co-development deals that have occurred in the NSCLC market since 2006

Reasons to buy

The report will enhance your decision-making capability by allowing you to:
- Understand the NSCLC pipeline and the factors that indicate that it is becoming more innovative

- Observe detailed profiles for promising pipeline products and gain insights into how they are likely to compete in the market and who their main competitors will be

- Follow the trends in NSCLC clinical trial size and duration in relation to industry averages

- Assess the potential risk of future developmental programs for NSCLC therapeutics, depending on the mechanism of action, by considering the recorded clinical trial failure rates

- Observe the potential growth patterns expected for the NSCLC market over the forecast period

- Identify which countries are expected to contribute the most to this growth and devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the NSCLC market

- Accelerate and strengthen your market position by identifying key companies for strategic partnerships

Contents:

1 Table of Contents
   1.1 List of Tables
   1.2 List of Figures

2 Introduction
   2.1 Symptoms
   2.2 Etiology
   2.3 Pathophysiology
   2.4 Co-morbidities and Complications
   2.5 Diagnosis
   2.5.1 Physical Examination
   2.5.2 Sputum Cytology
   2.5.3 Imaging Tests
   2.5.4 Biopsy
   2.6 Classification
   2.6.1 Adenocarcinoma
   2.6.2 Squamous Cell Carcinoma
   2.6.3 Large Cell Carcinoma
   2.7 Epidemiology
   2.8 Prognosis and Disease Staging
   2.8.1 Staging
   2.9 Treatment Options
   2.9.1 Surgery and Radiation Therapy
   2.9.2 Pharmacological
   2.9.3 Treatment Algorithms and Prescribing Habits

3 Marketed Products
   3.1 Therapeutic Landscape
   3.1.1 Alimta (pemetrexed disodium) – Eli Lilly and Company
   3.1.2 Abraxane (nab-paclitaxel) – Celgene
   3.1.3 Iressa (gefitinib) – AstraZeneca
   3.1.4 Tarceva (erlotinib hydrochloride) – F. Hoffmann-La Roche
   3.1.5 Xalkori (crizotinib) – Pfizer
   3.1.6 Avastin (bevacizumab) – F. Hoffmann-La Roche
   3.1.7 Gilotrif (afatinib) – Boehringer Ingelheim
   3.2 Comparative Efficacy and Safety

4 Pipeline Products
   4.1 Overall Pipeline
   4.2 Pipeline Analysis by Molecule Type
   4.3 Pipeline Analysis by Mechanism of Action
   4.4 Clinical Trials
4.4.1 Failure Rate
4.4.2 Patient Enrollment and Clinical Trial Size
4.4.3 Duration
4.5 Promising Drug Candidates in the Pipeline
4.5.1 Ramucirumab (IMC-1121B) – Eli Lilly and Company
4.5.2 Necitumumab (IMC-11F8) – Eli Lilly and Company
4.5.3 Onartuzumab (MetMab) – F. Hoffmann-La Roche
4.5.4 Ganetesplib (STA-9090) – Synta
4.5.5 Nintedanib (BIBF1120) – Boehringer Ingelheim
4.5.6 Dacomitinib (PF-00299804) – Pfizer
4.5.7 LDK378 – Novartis
4.5.8 Yervoy (ipilimumab) – Bristol-Myers Squibb
4.5.9 Nivolumab (BMS-936558/ONO-4538) – Bristol Myers Squibb

5 Market Forecast to 2019

5.1 Geographical Markets
5.1.1 APAC Market
5.1.2 India
5.1.3 Australia
5.1.4 China
5.1.5 Japan
5.2 Drivers and Barriers for the Disease Market
5.2.1 Drivers
5.2.2 Barriers

6 Deals and Strategic Consolidations

6.1 Major Co-development Deals
6.1.1 OxOnc Enters Co-development Agreement with Pfizer for Crizotinib
6.1.2 SFJ Pharma Enters Co-development Agreement with Pfizer for Dacomitinib
6.1.3 Merck Enters Co-development Agreement with Endocyte for Cancer Drug
6.1.4 Roche Enters Co-development Agreement with Clovis
6.1.5 Abbott Laboratories Enters Co-development Agreement with GlaxoSmithKline

6.2 Major Licensing Deals
6.2.1 Chugai Enters Licensing Agreement with Roche for Onartuzumab and Lebrikizumab
6.2.2 Azaya Enters Licensing Agreement with CANbridge Life Sciences for ATI-1123
6.2.3 Merck Expands Licensing Agreement with Biomira
6.2.4 Clovis Enters Licensing Agreement with Avila Therapeutics

7 Appendix

7.1 All Pipeline Drugs by Phase
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 IND-filed
7.1.4 Phase I
7.1.5 Phase II
7.1.6 Phase III
7.1.7 Undisclosed
7.2 Market Forecasts to 2019
7.2.1 APAC
7.2.2 India
7.2.3 Australia
7.2.4 China
7.2.5 Japan
7.3 Market Definitions
7.4 Abbreviations
7.5 Bibliography
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Primary Research
7.6.4 Therapeutic Landscape
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Expert Panel Validation
7.8 Contact Us
7.9 Disclaimer

1.1 List of Tables

Table 1: Non-Small Cell Lung Cancer Market, Common Symptoms of Non-Small Cell Lung Cancer
Table 2: Non-Small Cell Lung Cancer Market, Risk Factors of Non-Small Cell Lung Cancer Market
Table 3: Non-Small Cell Lung Cancer Market, American Joint Committee on Cancer's Tumor Node Metastasis Staging System, 2010
Table 4: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Discovery), 2013
Table 5: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Preclinical), 2013
Table 6: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (IND-filed), 2013
Table 7: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Phase I), 2013
Table 8: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Phase II), 2013
Table 9: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Phase III), 2013
Table 10: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Undisclosed), 2013
Table 11: Non-Small Cell Lung Cancer Market, Asia-Pacific, Market Forecast, 2012–2019
Table 12: Non-Small Cell Lung Cancer Market, India, Market Forecast, 2012–2019
Table 13: Non-Small Cell Lung Cancer Market, Australia, Market Forecast, 2012–2019
Table 14: Non-Small Cell Lung Cancer Market, China, Market Forecast, 2012–2019
Table 15: Non-Small Cell Lung Cancer Market, Japan, Market Forecast, 2012–2019

1.2 List of Figures

Figure 1: Non-Small Cell Lung Cancer Market, Asia-Pacific, Distribution of Prevalence Population, 2012–2019
Figure 2: Non-Small Cell Lung Cancer Market, Treatment Algorithm for Early and Advanced Localized Tumors Stages IIIA and IIIB, 2013
Figure 3: Non-Small Cell Lung Cancer Market, Treatment Algorithm for Early and Advanced Localized Tumors Stages IIIA and IIIB, 2013
Figure 4: Non-Small Cell Lung Cancer Market, Treatment Algorithm for Advanced Metastatic Tumors, 2013
Figure 5: Non-Small Cell Lung Cancer Market, Global, Annual Sales, 2012
Figure 6: Non-Small Cell Lung Cancer Market, Global, Alimta (pemetrexed disodium) Annual Sales ($bn), 2004–2012
Figure 7: Non-Small Cell Lung Cancer Market, Global, Abraxane (nab-paclitaxel) Annual Sales ($m), 2009–2012
Figure 8: Non-Small Cell Lung Cancer Market, Global, Iressa (gefitinib) Annual Sales ($m), 2005–2012
Figure 9: Non-Small Cell Lung Cancer Market, Global, Tarceva (erlotinib) Annual Sales ($bn), 2006–2012
Figure 10: Non-Small Cell Lung Cancer Market, Global, Xalkori (crizotinib) Annual Sales ($m), 2012–2013
Figure 11: Non-Small Cell Lung Cancer Market, Global, Avastin (bevacizumab) Annual Sales ($bn), 2006–2012
Figure 12: Non-Small Cell Lung Cancer Market, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2013
Figure 13: Non-Small Cell Lung Cancer Market, Global, Pipeline by Stage of Development, Program Type and Route of Administration, 2013
Figure 14: Non-Small Cell Lung Cancer Market, Global, Pipeline by Molecule Type and Stage of Development, 2013
Figure 15: Non-Small Cell Lung Cancer Market, Global, Pipeline by Mechanism of Action, 2013
Figure 16: Non-Small Cell Lung Cancer Market, Global, Pipeline by Mechanism of Action, Molecule Type and Stage of Development (Number), 2013
Figure 17: Non-Small Cell Lung Cancer Market, Global, Clinical Trial Failure Rate (%), 2013
Figure 18: Non-Small Cell Lung Cancer Market, Global, Clinical Trial Size (Participants), 2013
Figure 19: Non-Small Cell Lung Cancer Market, Global, Pipeline Clinical Trial Duration (months), 2013
Figure 20: Non-Small Cell Lung Cancer Market, Asia-Pacific, Market Size, 2012–2019
Figure 21: Non-Small Cell Lung Cancer Market, India, Market Size, 2012–2019
Figure 22: Non-Small Cell Lung Cancer Market, Australia, Market Size, 2012–2019
Figure 23: Non-Small Cell Lung Cancer Market, China, Market Size, 2012–2019
Figure 24: Non-Small Cell Lung Cancer Market, Japan, Market Size, 2012–2019
Figure 25: Non-Small Cell Lung Cancer Market, Global Deals by Value, Year and Stage of Development, 2006–2013
Figure 26: Non-Small Cell Lung Cancer Market, Global, Deals by Phase, Molecule Type and Mechanism of
Figure 27: Non-Small Cell Lung Cancer Market, Global, Co-development Deals by Geography, 2006–2013
Figure 28: Non-Small Cell Lung Cancer Market, Global, Licensing Deals by Geography, 2006–2013
Figure 29: Market Forecasting Model (Example)

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2775079/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

| Product Name: | NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool |
| Web Address: | http://www.researchandmarkets.com/reports/2775079/ |
| Office Code: | SC |

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 4995</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 14985</td>
</tr>
<tr>
<td>Site License:</td>
<td>USD 9990</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address:</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by Wire Transfer: Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marketing Code: ____________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp